Key result
Diabetes significantly increases the risk of heart failure and diabetic cardiomyopathy, necessitating comprehensive management with guideline-directed therapies and careful selection of antidiabetic drugs.
This review highlights the critical intersection of diabetes and heart failure, emphasizing the pathophysiology of diabetic cardiomyopathy and the need for cardiovascular-safe glucose-lowering therapies.
Highlights need for multidisciplinary diabetes-HF management; leaves open optimal antidiabetic selection pending dedicated trials.
Diabetes ranks among most common chronic disease in the world. In the year 2015, 415 million people were suffering from diabetes and the number is expected to swell to 642 millions in the year 2042. Hypertension, ischaemic heart disease and valvular heart disease increase the risk of Heart Failure (HF) in diabetes. In absence of these also, diabetics are more vulnerable for HF. This has led to the concept of diabetic cardiomyopathy. Diabetic cardiomyopathy can present as HF with reduced ejection fraction or preserved ejection fraction. Treatment is with diuretics, ACE inhibitors, ARBS and Beta blockers.
No takes yet. Share an insight, caveat, or question.
Mishra et al. (2017) conducted a review in Diabetes and Heart Failure. Diabetes significantly increases the risk of heart failure and diabetic cardiomyopathy, necessitating comprehensive management with guideline-directed therapies and careful selection of antidiabetic drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: